Cosmos Health (Cosmos Health) Risk Assessment

View and export this data going back to 2010. Start your Free Trial

What is Cosmos Health Risk Assessment?

Risk Assessment represents the investment risk of a stock derived from our exclusive method. It suggests how risky the investment opportunity is based on the valuation and the fundamental performance of the stock. It is derived from following key aspects:

1. GuruFocus internally developed valuations of the stock, such as GF valuation.
2. Quality Rank, a business quality indicator developed by GuruFocus.
3. Fundamental performance: Piotroski F-Score, Altman Z-Score, Beneish M-Score, etc.
4. Growth opportunities: 5-year revenue growth rate, 5-Year EPS without NRI Growth Rate, etc.

Value investors are always willing to find undervalued stocks. However, not all the undervalued stocks are good deals, we should also be careful of how risky the investment opportunity is. We believe that if the company's financial strength and profitability are strong, and the stock price is within a reasonable range of the GF valuation, or stock has a high return with its price being undervalued, then it might be a good investment opportunity with low risk.

Based on those aspects listed above, GuruFocus believes the risk assessment of Cosmos Health is: High Risk: High uncertainty.

Competitive Comparison of Cosmos Health's Risk Assessment

For the Medical Distribution subindustry, Cosmos Health's Risk Assessment, along with its competitors' market caps and Risk Assessment data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Cosmos Health's Risk Assessment Distribution in the Medical Distribution Industry

For the Medical Distribution industry and Healthcare sector, Cosmos Health's Risk Assessment distribution charts can be found below:

* The bar in red indicates where Cosmos Health's Risk Assessment falls into.

Cosmos Health (NAS:COSM) Risk Assessment Explanation

Based on the four aspects listed above, GuruFocus provides the following 7 evaluations:

All-in-One Screener Examples (1)
Low Risk: Strong fundamentals, worth long-term holding
Moderate Risk: Sensitive, better choose undervalued stock
High Risk: High uncertainty with risk-return tradeoff
High Risk: Good fundamentals, beware of shrinking business
High Risk: Sensitive to economic or industry trends
High Risk: High uncertainty
No Data: Cannot be evaluated

(1) These are some simple examples. You can access our Risk Assessment filter under All-in-One Screener’s Fundamental tab and set your own criteria.

Cosmos Health Risk Assessment Related Terms

Thank you for viewing the detailed overview of Cosmos Health's Risk Assessment provided by GuruFocus.com. Please click on the following links to see related term pages.

Cosmos Health (Cosmos Health) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Distribution » Cosmos Health Inc (NAS:COSM) » Definitions » Risk Assessment

Comparable Companies

Traded in Other Exchanges

V67A:Germany

Address

141 West Jackson Boulevard, Suite 4236, Chicago, IL, USA, 60604

Website

https://www.cosmoshold.com

Cosmos Health Inc is engaged in the nutraceuticals sector through its own proprietary lines of products 'Sky Premium Life' and 'Mediterranation'. Additionally, the firm is operating in the pharmaceutical sector through the provision of a broad line of branded over-the-counter drugs and branded and generic medicines. The company's focus will be on Branded Pharmaceuticals, Over-the-Counter medicines, and Generic Pharmaceuticals. It provides its products to wholesale drug distributors, wholesalers, and retail healthcare providers.

Executives

Grigorios Siokas	10 percent owner	5 AG. GEORGIOU STR., PILEA, THESSALONIKI J3 TK57001
Suhel Bhutawala	director	141 WEST JACKSON BOULEVARD, SUITE 4236, CHICAGO IL 60604
Nikolaos Bardakis	officer: Chief Operating Officer	141 WEST JACKSON BOULEVARD, SUITE 4236, CHICAGO IL 60604
Manfred Ziegler	director	141 WEST JACKSON BOULEVARD, SUITE 4236, CHICAGO IL 60604
Anastasios Aslidis	director	11 CANTERBURY LANE, WATCHUNG NJ 07069
Pavlos Ignatiades	officer: Chief Operating Officer	KALAPATHAKI 5, PANORAMA, THESSALONIKI J3 55236
Georgios Terzis	officer: Chief Financial Officer	2 MELITOS STR., NEA SMIRNI, ATTICA J3 17121
Peter Goldstein	director	151 NORTH NOB HILL ROAD SUITE 321, FORT LAUDERDALE FL 33324
John James Hoidas	director	9301 S. HARLEM AVENUE, OAK LAWN, CHICAGO IL 60453
Dimitrios Goulielmos	director, 10 percent owner, officer: CEO	141 WEST JACKSON BLVD, SUITE 4236, CHICAGO IL 60604
Panagiotis Tolis	director, officer: Secretary	PERICLEOUS 50 STREET, ATHENS J3 15232
Panagiotis Drakopoulos	director, 10 percent owner, officer: CEO	200 SOUTH WACKER DRIVE, SUITE 300, CHICAGO IL 60606
Vasileios Mavrogiannis	director, 10 percent owner, officer: CFO	TERTSETI 23 STREET, KESARIANI J3 16122